Infinitopes raises €14.7M Seed round
1 May 2024· Oxford, United Kingdom· biotechnology, oncology, ai, immunotherapy, software_hardware
The funding will accelerate the installation of LC-MS/MS mass spectrometer equipment, enhancing the company's proprietary tumour antigen discovery and computational immunobiology/AI/machine learning techniques to identify and rank optimal target combinations to combat five different types of cancers. It will also support the start of the phase I/IIa study for its lead vaccine, ITOP1.
Investors
LeadOctopus Ventures
Also participating
Kindred CapitalCancer Research HorizonsCancer Research InstituteCRIS Cancer FoundationManta RayMartlet CapitalMeltwind AdvisorySaras CapitalWilbe Capitalexpert angel investors
About Infinitopes
Stage
Seed
Headquarters
Oxford, United Kingdom
Founded
2021
Team Size
6–20
Sectors
biotechnologyoncologyaiimmunotherapysoftware_hardware